Patrizia Cavazzoni, formerly the top regulator of the drug division of the FDA, will join Pfizer as chief medical officer.

Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.

Curay, the acting director of the FDA’s Center for Drug Evaluation and Research, internally announced her retirement Monday.

The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire from the agency. The seven-year FDA veteran communicated the decision in ...

"It is the FDA's role to ensure that drugs are safe and effective," said Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, in a news release on Thursday.

Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.

The FDA says oral phenylephrine, used in many over-the-counter cough and cold medicines, "is not effective as a nasal decongestant." ...

"It is the FDA’s role to ensure that drugs are safe and effective," Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a statement.

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief medical officer, bringing back an industry veteran to lead its ...

"It is the FDA’s role to ensure that drugs are safe and effective," Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a statement.

The Food and Drug Administration announced Wednesday its intention to remove oral phenylephrine, a common ingredient in over-the-counter cough and cold medicines, from the market.

Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.